DENTSPLY SIRONA

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic and orthodontic dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dentsply Sirona (XRAY) exceeds Q4 expectations, focuses on innovation

Dentsply Sirona (XRAY) reported strong financial performance in Q4 2022, with a strategic focus on digitalization and innovation. Despite challenges in organic sales and supply chain constraints, the company aims for margin improvement and growth opportunities through investments and pricing strategies. Restructuring efforts and acquisitions are set to drive profitability and market share gains.

Dentsply Sirona reports robust Q1 growth, eyes digital innovation

Dentsply Sirona's strong Q1 performance driven by Consumables and Aligners segments.
Challenges include mixed regional performance and cautious outlook on equipment demand.
Opportunities lie in digitalization, DSO partnerships, and growth in China and EPS targets.
Overall, a positive outlook with strategic focus on innovation and customer experience.

Dentsply Sirona exceeds Q2 expectations, eyes growth amid challenges

Dentsply Sirona reported strong financial performance in Q2 2023, exceeding expectations and raising full-year outlook across key financial metrics.
The company's strategic focus on growth, profitability, and digitalization, coupled with investments in key regions and product innovation, positions it for sustained success.
While facing challenges in certain markets and operational areas, Dentsply Sirona remains optimistic about opportunities for growth, innovation, and value creation in the dental industry.
Overall, Dentsply Sirona's performance highlights operational strengths, market positioning, and a forward-looking approach to driving shareholder value and market expansion.

DENTSPLY SIRONA reports mixed Q3 results, focuses on innovation and growth

DENTSPLY SIRONA's Q3 performance showed mixed results with challenges in certain markets but strength in key segments like CAD/CAM and Aligners.
The company is focused on driving value through innovation, maintaining a commitment to long-term plans, and navigating external challenges with confidence.
Despite headwinds, DENTSPLY SIRONA remains within guidance range for the year, with a strategic focus on volume growth and market expansion opportunities.

DENTSPLY SIRONA anticipates double-digit EPS growth in 2024

DENTSPLY SIRONA's Q4 2023 performance showed growth in key segments, with strategic initiatives set for 2024 as an inflection year for double-digit EPS growth.
The company is focusing on innovation, SKU optimization, and operational efficiency to drive profitability and revenue growth.
Challenges lie in certain segments and the need for organic growth normalization by 2025, but opportunities exist in new product launches and margin expansion.
Overall, DENTSPLY SIRONA is poised for accelerated profitable growth, with 2024 expected to be a pivotal year for improved performance.

DENTSPLY SIRONA reports mixed Q1 performance amidst innovation focus

DENTSPLY SIRONA navigated challenges in Q1 with a focus on innovation, sustainability, and strategic updates. While facing headwinds in certain segments and markets, the company aims to capitalize on growth opportunities through product launches and strategic initiatives.

DENTSPLY Sirona navigates revenue decline with strategic restructuring plans

DENTSPLY Sirona's Q2 performance reflects revenue decline and margin contraction, prompting strategic restructuring and focus on customer-centric initiatives. While facing challenges from macroeconomic factors and restructuring impacts, the company aims to leverage opportunities in shareholder returns and market dynamics to drive growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--WellAir, a leading indoor air disinfection and purification solutions provider, today announced that Kari Dixon has been appointed as the company's President and Chief Executive Officer. As a capital markets veteran, Dixon has served as WellAir's Chief Financial Officer since she joined the company in 2021. Todd M. Pope has been named Vice-Chair of the Board of Directors. "It has been an honor to serve as the President and CEO of WellAir during the

WellAir Announces Kari Dixon as President and Chief Executive Officer

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Dentsply Sirona, Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) on behalf of Dentsply stockholders. Our investigation concerns whether Dentsply has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 19, 2022, the Company issued a press release announci

DENTSPLY ALERT: Bragar Eagel & Squire, P.C. is Investigating Dentsply Sirona, Inc. on Behalf of Dentsply Stockholders and Encourages Investors to Contact the Firm

HC Wainwright has cut the price target for Dentsply Sirona Inc (NASDAQ: XRAY) from $58 to $48 (17% upside), reiterating the Neutral rating. The analysts have adjusted 2022 projections to reflect lower than expected Q1 FY22 earnings.

Read Why HC Wainwright Cut Price Target For Dentsply Sirona

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dentsply Sirona Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Dentsply investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Dentsply Sirona Inc. (XRAY) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Dentsply Sirona Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) investors concerning the Company's possible violations of federal securities laws. On April 19, 2022, Dentsply stated that the Company's Chief Executive Officer had been terminated, effective immediately, and will “cease to serve as a member of the Company's Board.” On this news, Dentsply's stock fell $6.52, or 13.4%, to close a

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Dentsply Sirona Inc. (XRAY) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Dentsply Sirona Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 19, 2022, Dentsply stated that the Company's Chief Executive Officer had been terminated, effective immediately, and will “cease to serve as a member of the Compa

The Law Offices of Frank R. Cruz Announces Investigation of Dentsply Sirona Inc. (XRAY) on Behalf of Investors

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

MILWAUKEE , April 20, 2022 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against DENTSPLY SIRONA (NASDAQ: XRAY). The investigation results from inaccurate statements DENTSPLY SIRONA may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against DENTSPLY SIRONA Inc.

Dentsply Sirona Inc (NASDAQ: XRAY) appointed John Groetelaars, who serves on Dentsply Sirona's Board of Directors, as Interim Chief Executive Officer.  He succeeds Don Casey, who has been terminated as CEO, and will cease to serve as a member of the Company's Board,.

Why Are Dentsply Sirona Shares Plummeting Today?

Why Dentsply Sirona Stock Is Sinking Today

Shares of Dentsply Sirona Inc. XRAY, -0.71% tumbled 10.3% toward an 18-month low in premarket trading Tuesday, after the dental products maker said it "terminated" Chief Executive Donald Casey, and warned of a first-quarter earnings shortfall. The company did not provide a reason for Casey's termination, only that it was "effective immediately," and that he would cease to serve on the company's board.

Dentsply Sirona stock tumbles after CEO terminated, downbeat earnings outlook

John Groetelaars Named Interim Chief Executive Officer

Dentsply Sirona Provides Corporate Update

CHARLOTTE, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced that Executive Vice President and Chief Financial Officer Jorge Gomez has resigned from the Company, effective May 6, 2022, to assume a CFO position at another public company. The Company is initiating a search process to identify its next CFO.

Dentsply Sirona CFO Jorge Gomez Resigns to Assume CFO Position at Another Public Company

CHARLOTTE, N.C., April 06, 2022 (GLOBE NEWSWIRE) --  DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that Mr. John P. Groetelaars has been appointed to its Board of Directors (the “Board”), increasing the size of its Board from eleven to twelve members.

Dentsply Sirona Announces Appointment of Mr. John P. Groetelaars as New Board Member

CHARLOTTE, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 5, 2022 at 8:30 am ET to review its financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

Dentsply Sirona to Host First Quarter Conference Call on May 5th

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock?

Why Is Dentsply (XRAY) Down 8.5% Since Last Earnings Report?

CHARLOTTE, N.C., March 18, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that the Company will participate in the Piper Sandler Virtual Dental Day. Don Casey, Chief Executive Officer, is scheduled to participate in a fireside chat discussion on Tuesday, March 29, 2022 at 1:00 pm ET.

Dentsply Sirona to Participate in the Piper Sandler Virtual Dental Day

Let's see if DENTSPLY SIRONA (XRAY) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick DENTSPLY SIRONA (XRAY) Stock?

Dentsply Sirona (XRAY) CEO, Don Casey on Q4 2021 Results - Earnings Call Transcript

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) fourth-quarter results benefit from Technologies & Equipment business.

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Miss Estimates

Dentsply Sirona Inc's (NASDAQ: XRAY) Q4 FY21 sales increased 0.6% Y/Y to $1.09 billion, missing the consensus of $1.13 billion. Adjusted EPS decreased to $0.76 from $0.87 a year ago and below the consensus of $0.79.

Dentsply Sirona's Q4 Falls Short Of Expectations, FY22 Sales Outlook Lags Street View

Dentsply (XRAY) delivered earnings and revenue surprises of -3.80% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dentsply International (XRAY) Misses Q4 Earnings and Revenue Estimates

CHARLOTTE, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year 2021.

Dentsply Sirona Reports Fourth Quarter and Full Year 2021 Results

Dentsply Sirona (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Dentsply Sirona (XRAY) Ahead of Earnings?

Dentsply Sirona's revenue will grow at a CAGR of high-single-digits in the long term driven by its clear aligner business. The company's Byte and Propel Orthodontics acquisitions will diversify its clear aligner business.

News for DENTSPLY SIRONA Stock (XRAY)